文献速递急性肾损伤

多措并举急性肾损伤干预方案的成本效果随机对照试验证据

Randomized Controlled Trial Evidence of Cost-Effectiveness of a Multifaceted AKI Intervention Approach.
PubMed 文献 · Kidney Int Rep · 2020-12-16

Tackling AKI 为多中心、实用性、阶梯整群随机试验,评估电子预警、集束化管理和教育项目组成的多层面 AKI 干预;研究期内共 24,059 例 AKI 发作,18,887 例次住院患者存活出院。决策分析模型显示干预使每次 AKI 住院费用由 £5065 降至 £4333,增量节省 £732/次住院;每质量调整生命年成本由 £61,194 降至 £51,161,在 £20,000/QALY 支付意愿阈值下具有成本效果的概率为 90%。

要点

  • 多层面 AKI 干预每例住院节省 £732,并缩短住院时间
  • 干预组每 QALY 成本 £51,161,低于对照组 £61,194
  • £20,000/QALY 阈值下干预具成本效果的概率为 90%

核心结论

  • 在英国国家医疗服务体系内,组织层面的 AKI 护理改进可降低住院费用并具成本效果。

研究设计与样本

  • 多中心、实用性、阶梯整群随机试验 Tackling AKI 的临床数据;从支付方(英国国家医疗服务体系)角度构建决策分析树模型,采用概率敏感性分析,仅计入直接医疗费用。
  • 研究期间共 24,059 例 AKI 发作,其中 18,887 例次住院患者存活出院。

主要发现

  • 所有 AKI 分期合并分析时,每次 AKI 住院费用对照组为 £5065、干预组为 £4333,干预带来每次住院 £732 的增量成本节省。
  • 将 AKI 分期作为独立变量纳入时获得类似结果。
  • 每质量调整生命年成本对照组为 £61,194、干预组为 £51,161。
  • 在每质量调整生命年 £20,000 的支付意愿阈值下,干预相较标准护理具成本效果的概率为 90%。

关键数值与推荐

  • 每次 AKI 住院费用:对照组 £5065,干预组 £4333,增量节省 £732。
  • 每 QALY 成本:对照组 £61,194,干预组 £51,161。
  • 支付意愿阈值 £20,000/QALY 下,干预具成本效果的概率为 90%。

临床怎么用

  • 支持在组织层面推广电子预警联合集束化管理与教育的 AKI 干预,以降低住院费用并具成本效果。

局限性

  • 成本效果分析基于决策分析模型,经济与效用数据来自相关已发表文献而非试验直接测量。
  • 分析仅计入直接医疗费用,未纳入间接成本。
  • 全文未报告模型时限、贴现率及概率敏感性分析的具体参数分布。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Acute kidney injury (AKI) is associated with increased health care utilization and higher costs. The Tackling AKI study was a multicenter, pragmatic, stepped-wedge cluster randomized trial that demonstrated a reduced hospital length of stay after implementation of a multifaceted AKI intervention (e-alerts, care bundle, and an education program). We tested whether this would result in cost savings. METHODS: A decision-analytic tree model from the payer perspective (National Health Service in the United Kingdom) was generated on which cost-effectiveness analyses were performed using a probabilistic sensitivity analysis, accounting only for direct medical costs. Clinical data from the Tackling AKI study were used as inputs and economic and utility data derived from relevant published literature. RESULTS: A total of 24,059 AKI episodes occurred during the study period, and in 18,887 admissions the patient was discharged alive. When all AKI stages were considered together, the cost per AKI admission was £5065 in the control arm and £4333 in the intervention arm, representing an incremental cost saving of £732 per admission with the intervention. Similar results were obtained when AKI stages were included as separate variables. Costs per quality-adjusted life year were £61,194 in the control group and £51,161 in the intervention group. At a willingness to pay threshold of £20,000 per quality-adjusted life year, the probability of the intervention being cost-effective compared with standard care was 90%. CONCLUSION: An organizational level approach to improve standards of AKI care reduces the cost of hospital admissions and is cost effective within the National Health Service in the United Kingdom.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Selby NM, Korrodi-Gregório L, Casula A, et al. Randomized Controlled Trial Evidence of Cost-Effectiveness of a Multifaceted AKI Intervention Approach. Kidney Int Rep. 2020. PMID: 33732978. doi:10.1016/j.ekir.2020.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。